Targeted PSMA Radionuclide Drug Conjugates Market Size to Lead USD 2.15 Billion by 2035

The global targeted PSMA radionuclide drug conjugates market was valued at USD 1.99 billion in 2025 and is projected to reach USD 4.15 billion by 2035, growing at a CAGR of 7.60%, driven by rising prostate cancer prevalence and advancements in targeted radioligand therapies.

Targeted PSMA Radionuclide Drug Conjugates Market Statical Scope

The targeted PSMA radionuclide drug conjugates (RDCs) are a polished and proficient cancer therapy. The therapy serves radioactive isotopes straight to the cells showing the PSMA indication. Learning the rising advancement in modern prostate cancer treatment, the market’s homing molecule effectively spots the radioactive payload and hazardous cancer area to end the stress. Highlighting the buildup of conjugate includes targeting ligand, radionuclide (payload), chelator and linker. Further, the process promotes the definitive potential of different types of radiation payloads.

The unique space for the targeted PSMA radionuclide drug conjugates in the healthcare and the great position of lutetium Lu-177 vipivotide tetraxetan by Novartis is gaining traction in the market. This recognition fuels awareness and value of the market, proving the contribution to healthcare. The commendable investment, M&A, and theranostic benefits are empowering the market with sincere precision.

Targeted PSMA Radionuclide Drug Conjugates Market Share, By Region, 2025 (%)

• North America – The North America regional segment dominated the market by 42% of share. The growing adoption of PSMA-PET imaging and a robust clinical portfolio are bringing more focus to North American clinical trials. While the regulatory cooperation is a huge support to the regional market.
• Asia-Pacific – Asia Pacific rises by 20% with the effective involvement of South Korea, Japan, and China, with either their strategies or regulatory shifts. The initiatives by Asian researchers are establishing novel agents that strengthen the regional market and regional alliances.
• Europe – Europe leads by 28% with the best market exposure and theranostics advancement, bolstering the regional market. The surge in combination therapies, new ligand development and alpha-emitter establishment is accelerating the regional market growth.
• Latin America – Latin America covers 6% of the share due to the extension of nuclear medicine infrastructure, with the regional modern regulatory system supporting the market. The reasonable clinical trials cost in the region welcomes the core development of the market in the regional healthcare.
• Middle East & Africa – MEA grows by 4% with the growing cancer cases, and a robust infrastructure ecosystem for nuclear drugs helps the expansion of the market. The cooperative supply chain and regulatory frameworks acts favourable for managing short-term radioactive materials.

Targeted PSMA Radionuclide Drug Conjugates Market Share, By Type, 2025 (%)

• Monotherapy Products – The monotherapy products segment dominated the market by 62% of share, with the clear dominance of addition into the earlier stages. While the popular investment in alpha-emitters is paving the way for more potential opportunities in the market. The diversification of the platform brings more businesses to the segmental market.
• Combination Therapy Products – The combination therapy products segment scores 38% of share with a strong foundation and demand for combination therapies. The next generation radioisotopes are the hope for the segment to invest in investigational studies emerging in the market. The earlier line therapy is a research shift for the segment.

Targeted PSMA Radionuclide Drug Conjugates Market Share, By Application, 2025 (%)

• Hospital – The hospital segment dominated the market by 55% share, with the growing admission of cancer patients, and so the indications exceed covering extreme cases as well. The growing urgency of alpha-emitters are strengthning interest of the specialized cancer centers in this market.
• Clinic – The clinic segment grows by 30% due to the popular transition in alpha-emitting therapy and the surge of combination therapies, which tends to be a strong support to clinical researchers. The advancement in prostate cancer treatment with the boon of earlier lines is paving the way for the expansion of this market.
• Others – The pre-surgical settings featuring LuTectomy trial and other PSMAddition trials in the clinical settings are scoring 15% of the share. This fuels the best patient experience, covering full-fledged care.